- V30 -

LEADING WITH INNOVATION Were entering 2025 with momentum and strength. As the longstanding leader in HIV were committed to helping end the epidemic with the advancement of unprecedented longacting medications for both HIV prevention and treatment. Our diversified pipeline has the potential to deliver bestinclass therapies to address multiple myeloma and other types of cancer the rare liver disease primary biliary cholangitis and other diseases across our therapeutic areas. Delivering Transformative Therapies and Advancing Health Equity Through innovation were helping to build a healthier world for all people.